Patrys Limited (ASX:PAB) Receives R&D Tax Incentive Refund
Patrys Limited (ASX:PAB) secures $1.285 million in R&D Tax Incentive funding to advance its therapeutic antibody development initiatives.
Category: Healthcare
Chimeric Therapeutics (ASX:CHM) Advances Phase 1B AML Trial
Chimeric Therapeutics (ASX:CHM) advances its ADVENT-AML Phase 1B trial for newly diagnosed AML patients.
Invex Therapeutics Limited (ASX:IXC) Announces Positive Exenatide Results
Invex Therapeutics Limited (ASX:IXC) reports significant findings on Exenatide’s efficacy in neuronal cell survival using a 3D brain model for Alzheimer’s Disease.
Aura Energy Limited (ASX:AEE) Announces Significant Ore Reserve Growth
Aura Energy (ASX:AEE) has reported a 49% increase in Ore Reserves to 62.8Mt at the Tiris Uranium Project, enhancing project viability.
4DMedical Limited (ASX:4DX) Secures Contract with University of Chicago Medicine
4DMedical Limited (ASX:4DX) has secured a contract with University of Chicago Medicine to enhance lung imaging and care.
INOVIQ Limited (ASX:IIQ) Advances Exosome Therapy for Breast Cancer
INOVIQ Limited (ASX:IIQ) announces successful proof of concept for exosome therapy targeting breast cancer.
Aurora Energy Metals Limited (ASX:1AE) Reports Significant Recovery Improvements
Aurora Energy Metals (ASX:1AE) announces significant uranium recovery improvements in its Aurora Uranium Project, achieving rates over 85%.
Venus Metals Corporation Limited (ASX: VMC) Exploration Update
Venus Metals Corporation (ASX: VMC) reports promising exploration results from Copper Hills and Youanmi projects.
Maximus Resources Limited (ASX:MXR) Completes Follow-Up Drill Program
Maximus Resources Limited (ASX:MXR) completes follow-up drill program at Eagles Nest gold deposit; assay results expected in January 2025.
Anatara Lifesciences (ASX:ANR) Provides GaRP-IBS Trial Update
Anatara Lifesciences pauses recruitment for the GaRP-IBS trial, with pivotal results expected in March 2025 and a Share Purchase Plan closing soon.